Literature DB >> 16113361

Comparison of different techniques for purification of triamcinolone acetonide suspension for intravitreal use.

J García-Arumí1, A Boixadera, J Giralt, V Martinez-Castillo, F Gomez-Ulla, B Corcostegui, E García-Arumí.   

Abstract

BACKGROUND: Intravitreal triamcinolone has increasingly been used for the treatment of oedematous and neovascular diseases and purification of triamcinolone suspension may be important in order to avoid the potential toxic effects of the vehicle. The aim was to evaluate different techniques used to reduce the solvent agent benzyl alcohol (9.9 mg/ml) from a commercially prepared triamcinolone acetonide suspension.
METHODS: Different techniques were used to reduce the solvent agent benzyl alcohol: filter techniques using 0.22 mum or 5 mum pore size, and non-filter techniques using sedimentation or centrifugation. Quantification of triamcinolone acetonide and benzyl alcohol was performed by high pressure liquid chromatography (HPLC).
RESULTS: Benzyl alcohol concentration was decreased significantly in all the techniques used compared with the original commercial suspension (p<0.05), with no significant differences among them. The reduction was approximately one tenth of its original concentration. However, triamcinolone acetonide concentration differed significantly depending on the method used. Centrifugation method showed no differences versus the original commercial solution; sedimentation technique reduced the expected dose only 25%; the filter technique using a 5 mum pore size membrane reduced the expected dose to one fourth, while the filter technique using a 0.22 mum pore size membrane reduced the expected dose to 45%.
CONCLUSIONS: All the different techniques employed effectively reduced the concentration of benzyl alcohol. However, the final concentration of triamcinolone was much lower than expected using the filter techniques. The pore size membrane inversely influenced the final concentration, with part of the triamcinolone crystals probably being entrapped in the filter. Centrifugation is recommended as the best way of administering the drug.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16113361      PMCID: PMC1772839          DOI: 10.1136/bjo.2005.067744

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  12 in total

1.  Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration.

Authors:  Jost B Jonas; Imren Akkoyun; Wido M Budde; Ingrid Kreissig; Robert F Degenring
Journal:  Arch Ophthalmol       Date:  2004-02

2.  Determination of methylparaben, propylparaben, triamcinolone acetonide and its degradation product in a topical cream by RP-HPLC.

Authors:  L Matysová; R Hájková; J Sícha; P Solich
Journal:  Anal Bioanal Chem       Date:  2003-02-18       Impact factor: 4.142

3.  Pseudo-endophthalmitis after intravitreal injection of triamcinolone.

Authors:  F K P Sutter; M C Gillies
Journal:  Br J Ophthalmol       Date:  2003-08       Impact factor: 4.638

4.  Intravitreal triamcinolone acetonide for exudative age related macular degeneration.

Authors:  J B Jonas; I Kreissig; P Hugger; G Sauder; S Panda-Jonas; R Degenring
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

5.  Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations.

Authors:  T Hida; D Chandler; J E Arena; R Machemer
Journal:  Am J Ophthalmol       Date:  1986-02-15       Impact factor: 5.258

6.  Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone.

Authors:  J B Jonas; J K Hayler; A Söfker; S Panda-Jonas
Journal:  J Glaucoma       Date:  2001-08       Impact factor: 2.503

7.  Intravitreal triamcinolone for refractory diabetic macular edema.

Authors:  Adam Martidis; Jay S Duker; Paul B Greenberg; Adam H Rogers; Carmen A Puliafito; Elias Reichel; Caroline Baumal
Journal:  Ophthalmology       Date:  2002-05       Impact factor: 12.079

8.  Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy.

Authors:  J B Jonas; J K Hayler; A Söfker; S Panda-Jonas
Journal:  Am J Ophthalmol       Date:  2001-04       Impact factor: 5.258

9.  Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study.

Authors:  R J Antcliff; D J Spalton; M R Stanford; E M Graham; T J ffytche; J Marshall
Journal:  Ophthalmology       Date:  2001-04       Impact factor: 12.079

10.  Intravitreal injection of triamcinolone for diffuse diabetic macular edema.

Authors:  Jost B Jonas; Ingrid Kreissig; Antje Söfker; Robert F Degenring
Journal:  Arch Ophthalmol       Date:  2003-01
View more
  13 in total

1.  Purification of triamcinolone acetonide suspension for intravitreal injection.

Authors:  Enrique Soto-Pedre
Journal:  Br J Ophthalmol       Date:  2006-01       Impact factor: 4.638

2.  Influence of different purification techniques on triamcinolone yield and particle size spectrum.

Authors:  Peter Szurman; Radoslaw Kaczmarek; Gesine B Jaissle; Salvatore Grisanti; Matthias Lüke; Martin S Spitzer; Peter-Edgar Heide; Karl U Bartz-Schmidt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-09-28       Impact factor: 3.117

3.  Steroid differentiation: the safety profile of various steroids on retinal cells in vitro and their implications for clinical use (an American Ophthalmological Society thesis).

Authors:  Baruch D Kuppermann; Leandro Cabral Zacharias; M Cristina Kenney
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

4.  Comparison of 4 mg versus 20 mg intravitreal triamcinolone acetonide injections.

Authors:  A M Tammewar; L Cheng; O R Kayikcioglu; I A Falkenstein; I Kozak; M H Goldbaum; W R Freeman
Journal:  Br J Ophthalmol       Date:  2008-04-17       Impact factor: 4.638

5.  Triamcinolone reduces neovascularization, capillary density and IGF-1 receptor phosphorylation in a model of oxygen-induced retinopathy.

Authors:  M Elizabeth Hartnett; David J Martiniuk; Yuta Saito; Pete Geisen; Lynda J Peterson; Janet R McColm
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-11       Impact factor: 4.799

6.  Triamcinolone crystal size.

Authors:  Mark E Kleinman; Scott J Westhouse; Jayakrishna Ambati; P Andrew Pearson; Lawrence S Halperin
Journal:  Ophthalmology       Date:  2010-08       Impact factor: 12.079

7.  Vehicle of triamcinolone acetonide is associated with retinal toxicity and transient increase of lens density.

Authors:  Wang Kai; Jiang Yanrong; Li Xiaoxin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-02-02       Impact factor: 3.117

8.  Pharmacokinetic behavior of intravitreal triamcinolone acetonide prepared by a hospital pharmacy.

Authors:  Masako Oishi; Shinichiro Maeda; Noriyasu Hashida; Nobuyuki Ohguro; Yasuo Tano; Nobuo Kurokawa
Journal:  Jpn J Ophthalmol       Date:  2008-12-17       Impact factor: 2.447

9.  Subretinal injection of preservative-free triamcinolone acetonide and supernatant vehicle in rabbits: an electron microscopy study.

Authors:  Maurício Maia; Fernando Marcondes Penha; Michel Eid Farah; Eduardo Dib; André Príncipe; Acácio A S Lima Filho; Octaviano Magalhães; Edna Freymüller; Eduardo B Rodrigues
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-12-11       Impact factor: 3.117

10.  Retinal toxicity of triamcinolone's vehicle (benzyl alcohol): an electrophysiologic and electron microscopic study.

Authors:  Tamer A Macky; Dina Helmy; Nihal El Shazly
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-11-17       Impact factor: 3.535

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.